Intratumoral microdosing of PBA-0405 in patients with solid tumors

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

This study is testing a new way to deliver a cancer treatment directly into tumors to see how it affects the immune response in patients with certain types of solid tumors before their surgery.

Quick facts

• Phase: Early Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Pure Biologics S.A. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy, prednisone
• Locations: 4 sites (Shreveport, Louisiana and 3 other locations)
• Trial ID: NCT06273852 on ClinicalTrials.gov

What this trial studies

This multi-center, single-arm, open-label trial investigates the biological effects of PBA-0405 when administered in microdoses directly into tumors using the CIVO device. The CIVO device allows for precise delivery of subtherapeutic doses of multiple anti-cancer agents while marking injection sites with fluorescent microspheres for later analysis. Patients with head and neck squamous cell carcinoma, soft tissue sarcoma, or triple-negative breast cancer who are scheduled for surgical resection will receive the treatment prior to their surgery. The study aims to evaluate the immune response triggered by PBA-0405 within the tumor microenvironment.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with specific types of solid tumors scheduled for surgical resection.

Not a fit: Patients with tumors not eligible for the specified types or those who have had prior neoadjuvant therapy with progressive disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could enhance the effectiveness of cancer treatments by improving immune responses against tumors.

How similar studies have performed: While the use of microdosing in oncology is an emerging field, similar approaches have shown promise in early-phase studies, indicating potential for success.

Eligibility criteria

Inclusion Criteria:

1. Ability and willingness to comply with the study's visit and assessment schedule.
2. Male or female ≥ 18 years of age at Visit 1 (Screening).
3. Pathologic diagnosis of HNSCC, STS (see restrictions in Note below), or TNBC (see restrictions in Note below; TNBC defined as estrogen receptor negative \[\<1% positive tumor cells\], progesterone receptor negative \[\<1% positive tumor cells\], and human epidermal growth factor receptor 2 negative \[0 to 1+\]) with a tumor planned for surgical resection.

   Note: For STS, only the following subtypes are eligible: undifferentiated pleomorphic sarcoma, alveolar soft part sarcoma, synovial sarcoma, cutaneous angiosarcoma, or myxofibrosarcoma.

   Note: For TNBC, if prior neoadjuvant therapy, evidence of progressive disease, at the discretion of the investigator.
4. Ability and willingness to provide written informed consent. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
5. As assessed or confirmed by the surgeon, at least one lesion (primary tumor, recurrent tumor, metastatic tumor, or metastatic lymph node) that is surface accessible for CIVO injection that contains viable minimum tumor tissue volume and characteristics (e.g., based on clinical evaluation, available pre-operative imaging, pre-injection ultrasound imaging, or pathology reports indicating lesion with appropriate viable tumor volume without excessive cysts or necrosis) and for which there is a planned surgical intervention. The patient's presentation, surgical and pathology plan may determine whether a lesion is eligible with respect to a given CIVO MID needle configuration.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
7. Female patients who:

   * Are postmenopausal for at least one year before the screening visit, OR
   * Are surgically sterile, OR
   * Are of childbearing potential who agree to practice a highly effective method of contraception from the time of signing the ICF up to 3 months following the end of study participation OR agree to completely abstain from heterosexual intercourse.
   * Agree to refrain from donating ova during study participation.

Male patients, even if surgically sterile (i.e., status post-vasectomy), who:

* Agree to practice effective barrier contraception from the time of signing the ICF up to 3 months following the end of study participation OR agree to completely abstain from heterosexual intercourse.
* Agree to refrain from donating sperm during study participation.

Exclusion Criteria:

1. Tumors near or involving critical structures for which, in the opinion of the treating clinician, injection would pose undue risk to the patient.
2. Female patients who are:

   * Both lactating and breastfeeding, OR
   * Have a positive β-subunit human chorionic gonadotropin (β-hCG) pregnancy test at screening verified by the Investigator.
3. Any uncontrolled intercurrent illness, condition, serious medical or psychiatric illness, or circumstance that, in the opinion of the Investigator, could interfere with adherence to the study's procedures or requirements, or otherwise compromise the study's objectives.
4. HNSCC known to be of cutaneous origin.
5. Patients with uncontrolled autoimmune diseases (see Appendix 1 for examples) requiring systemic treatment
6. Patients with known HIV/AIDS.
7. Patients with known uncontrolled active hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] positive or detectable hepatitis B virus \[HBV\] DNA) or hepatitis C (defined as anti-hepatitis C virus antibody \[anti-HCV Ab\] positive and detectable hepatitis C virus \[HCV\] RNA) infection.

   Note: Hepatitis B and C screening tests are not required unless:
   * Patient has a known history of hepatitis B/C infection
   * Mandated by local health authority
8. Use of any of the following ≤ 3 weeks prior to CIVO injection:

   1. Systemic anti-cancer therapy (e.g., cytotoxic chemotherapy, targeted agents, or checkpoint inhibitor immunotherapy, etc.),
   2. Immunosuppressive drugs (e.g., calcineurin inhibitors)
   3. Biological response modifiers for autoimmune disease
   4. Systemic glucocorticoids: oral or parenteral corticosteroids at a dose ≥ 20 mg/day prednisone, or equivalent Note: physiologic replacement dosing of steroids (≤ 3 mg/m2/d prednisone or equivalent), low-dose corticosteroids for dye allergies prior to staging scans or use in anti-emetic prophylaxis for patients undergoing chemotherapy, or topical steroids, are allowed
   5. Hematopoietic growth factors
   6. Chemotherapy
   7. Local radiotherapy of the target lesion planned for CIVO injection and surgical resection
9. Patients who have received a live or live attenuated vaccine within 4 weeks of the baseline/screening visit.
10. Patients who have had allogenic tissue/solid organ transplant
11. Patients with an active infection requiring systemic therapy.
12. Patients for whom participation on this study results in a delay of planned surgical intervention.

Where this trial is running

Shreveport, Louisiana and 3 other locations

• LSU Health Sciences Center — Shreveport, Louisiana, United States (Recruiting)
• Oregon Health and Science University — Portland, Oregon, United States (Recruiting)
• University of Pennsylvania — Philadelphia, Pennsylvania, United States (Recruiting)
• Sarah Cannon Research Institute — Charleston, South Carolina, United States (Recruiting)

Study contacts

• Study coordinator: Presage Biosciences

Conditions Head and Neck Squamous Cell Carcinoma; Soft Tissue Sarcoma Adult; Triple Negative Breast Cancer; Pure Biologics; PBA-0405; TNBC; STS; HNSCC